The results of this trial demonstrated no observed dose-limiting toxicities, and a strong immune cell infiltrate into tumors as evidenced by a 4.0- and 2.5-fold post-treatment increase in CD8+ and CD4+ T cells, respectively, as well as the presence of tumor-specific CD8+ T cells [80]. The gene discussed is CD8A; the disease is neoplasm.